Macroenzyme: do not forget liver function tests.
Explore the source record for details and available documents.
Amylases↗
Biomedical subjects
T Mari
Publications and source records attributed to T Mari.
Coeliac disease and autoimmune cholangitis: a case report.
Autoimmune cholangitis can be associated with other autoimmune disorders. The case is described of a 58-ear-old female who developed severe microcytic anaemia resistant to oral iron treatment. Evaluation of the patient led to the diagnosis of coeliac disease, a rarely described association. Gluten-free diet and treatment with oral haematinics led to reversal of the anaemia.
Autoimmune Diseases↗
[A fatal case of postpartum Budd-Chiari syndrome in a woman with SLA].
We report a case of Budd Chiari syndrome with clinical onset during post partum in a patient with SLE. Etiopathogenetic correlations between pregnancy and BDS and between SLE and BDS are discussed, with particular regard to lupus anticoagulant factor. Furthermore, the diagnostic role of abdominal CT is emphasized.
Adult↗
[Segmentary veno-occlusive disease of the liver secondary to insecticide inhalation].
We report a case of venocclusive (VOD) disease secondary to inhalation of an insecticide. Pathological features of liver injury are illustrated with regard to patchy lesions shown by a new computer assisted colorimetric method. A possible role of immuno-complexes in the development of endothelium damage to centro-lobular veins is discussed.
Adult↗
Effect of somatostatin in controlling bleeding from esophageal varices.
A multicenter double-blind clinical trial was undertaken to evaluate the efficacy of a short-term somatostatin treatment versus a short-term vasopressin treatment on acute hemorrhage from esophageal varices in patients with liver cirrhosis and portal hypertension. Forty-nine patients with massive hemorrhage and endoscopic diagnosis of bleeding esophageal varices completed the study. Patients were randomly assigned to somatostatin treatment (24 patients: 250 micrograms/hr i.v. for 48 hrs) or vasopressin treatment (25 patients: 0.1 U/min i.v. for 48 hrs). The Sengstaken-Blakemore tube was utilized, when needed, for a six hour period. In case of failure the patients were crossed-over to the other treatment. Patients in whom the bleeding stopped at 48 hrs, were randomly assigned to somatostatin (250 micrograms/hr i.v.) or placebo for seven days. Bleeding stopped in 68% of patients treated with somatostatin and in 28% of patients treated with vasopressin (p less than 0.0013). Mortality rate was lower, but not significantly so, in the somatostatin group compared to the vasopressin group. No differences were noted between somatostatin and placebo in preventing bleeding recurrences. These data suggest that somatostatin, when combined if necessary with a 6 hour period of balloon tamponade, is more effective than vasopressin at low doses in controlling severe hemorrhage from esophageal varices in patients with liver cirrhosis and portal hypertension. A clinical use of somatostatin seems to be indicated in these patients.
Clinical Trials as Topic↗